As of July 2018, three of the company's programs — Clickotine, for smoking cessation; Clickadian, for insomnia; and ClickEMFT, for major depression — are in the efficacy trial phase.

In Summer 2018, Click Therapeutics receieved $17 million in investment from French pharma major Sanofi.